Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40b25e221408b9cde608f61b237aef22 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
filingDate |
2001-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_267bc7fbe6d2c39c8851e9d20ab0c462 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7f11a1a13f8b524f6043ca29e785e33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b66d3f5117d27ee0cf359f2ec80d4bf2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_714c55ee431949ec5176c263c789ed91 |
publicationDate |
2002-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-1132083-A3 |
titleOfInvention |
Use of zinc tranexamate in the treatment of diabetes |
abstract |
A new use of a zinc tranexamate compound in thentreatment of diabetes is disclosed. Oralnadministration of the compound adequately slowsndown absorption of glucose from digestive tracts byninhibiting α -glucosidase in vivo. The zincntranexamate compound is also effective in thentreatment of insulin-resistant type II diabetes. |
priorityDate |
2000-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |